About
About
About
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
​
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
​
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
​
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
​
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
​
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
​
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
​
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
​
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
​
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
​
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
​
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
​
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
Research &
Development
Code Pharma is well positioned to play a key role in the current race to develop a cure for HIV. Our drug Gammora - which was originally discovered at the Hebrew University in Israel - has a very good safety profile and very impressive activity in HIV, both under laboratory conditions and in our clinical trials.
Gammora eliminates the HIV infected cells in difference from the cocktail drugs used today which works on the virus itself.
Clinical studies
Gammora is a short synthetic peptide derived from HIV virus that was found in preclinical and clinical examinations to either:
​
1. Promote HIV-infected cells into self-induced death (apoptosis), and Lentivirus manipulation in the case of cancer therapy.
2. Leads to antiviral effect against RNA viruses.
Pipeline
Phase 1 clinical trial - Completed
A subsequent phase I clinical trial of Codivir in patients with COVID-19, approved by Brazil’s National Research Ethics Commission (CONEP) and conducted at Vera Cruz Hospital in São Paulo, Brazil, demonstrated a high safety profile while significantly suppressing viral replication in most of the fully assessed patients with an antiviral effect noted as early as three days. All patients recovered quickly after the treatment with Codivir and didn’t show any signs of side effects very often associated with COVID-19 infections.
Phase 2a clinical trial – Ongoing
Following the successful safety results of phase I study, the company is conducting a phase IIa randomized open label controlled study in Brazil, in HIV patients. Along with safety results, this study can indicate proof of concept for the drug efficacy in HIV patients.
​
Code Pharma has already received emergency approvals from several countries and is preparing for mass production of Gammora in different production sites worldwide based on the received orders.